secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ayala Pharmaceuticals, Inc. (—)
CIK:        0001100397
Form:       8-K
Filed at:   2023-01-25T23:59:59+00:00
Accession:  0001493152-23-002462
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Advaxis completes reverse merger with Ayala Pharmaceuticals; name change and board appointments
--------------------------------------------------------------------------------

- Merger closed Jan 19, 2023; Old Ayala stockholders received 0.1874 shares of New Ayala common stock per share.
- Company name changed from Advaxis, Inc. to Ayala Pharmaceuticals, Inc.; fiscal year unchanged.
- Directors James Patton and Richard Berman resigned; new directors appointed: Robert Spiegel, Murray Goldberg, Vered Bisker-Leib.
- Accounting treatment is a reverse acquisition; Old Ayala will be reflected as predecessor for future financials.
- Financial statements and pro forma information to be filed within 71 calendar days via amendment to this 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100397/000149315223002462/0001493152-23-002462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100397/000149315223002462/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-002462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer